Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL.

This article discusses how denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone mass density in knock-in mice that express chimeric RANKL. Denosumab treatment reduces bone resorption and inhibits osteoclastogenesis by inhibiting human RANKL. The treated mice were forced to form a chimeric form of RANKL which maintained bone resorption. Histomorphometry showed that denosumab reduces osteoclast numbers and increases bone volume.